Pfizer Inc. reaffirmed its full-year 2026 guidance, projecting Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00. This reaffirmation follows the disclosure of the company's Chief Financial Officer transition. Pfizer Inc. is a biopharmaceutical company that develops, manufactures, and markets medicines and vaccines.
